ONLY EIGHT RATS: Dr Jha Says Omicron Boosters Are "Substantial Upgrades" Despite Pharma Massively Cutting Corners

“These are substantial upgrades in our vaccines, in terms of their ability to prevent infection, to prevent transmission, certainly to prevent serious illness and death” -Dr Jha

This article has been made into a movie: ‘Skipping Almost All Studies, LYING US Govt Says Omicron mRNA Boosters WAY More Effective’

A New Low?

The US Government is now promising Americans a radically improved covid shot based on bloodwork from just 8 injected mice plugged into a model no one thinks works.

Brace yourself for the marketing onslaught pushing the mostly untested Omicron booster shots for people’s doses #5+. Despite the lack of data, the US federal government is praising the mRNA vax manufacturers for amazing advancements in efficacy:

“These are substantial upgrades in our vaccines, in terms of their ability to prevent infection, to prevent transmission, certainly to prevent serious illness and death” -Dr Jha, White House Covid-19 Response Coordinator

It seems like Moderna and Pfizer are now targeting different strains with their shots. Moderna claims to be tailored as a combination of BA.1 & original. Pfizer is targeting BA4, BA5 & the original. For some reason both companies’ shots are being called “bivalent” despite the Pfizer shot having three listed strains. According to a Pfizer press release the vax serum is half original formula and half BA4/BA5 targeting formula. The “strain selection” process makes little sense and raises a lot of questions, but that’s a topic for a future report.

Shortcuts Taken: A Pitiful LACK Of Data For Omicron Boosters

On August 16th, 2022 Covid Czar Dr Jha confessed in conversation with the US Chamber of Commerce President that the shots are only expected, not known, to be safe:

“These are- the booster- the new booster that is coming out in the fall is essentially a reformulation of something that we’ve already used. So I’d expect to see the same safety profile in pregnant women.” -Dr Jha White House Covid-19 Response Coordinator

Yet in the same interview he was also touting the new vaccines as massively improved, and this quote was what the media outlets really ran with.

“Again, we’re going to know more about this in the upcoming weeks and these vaccines will become available by early to mid September. But the big picture, bottom line, is these are substantial upgrades in our vaccines, in terms of their ability to prevent infection, to prevent transmission, certainly to prevent serious illness and death. And those vaccines are coming very, very soon. And so it’s going to be very important that people this Fall and Winter get the new shot. It’s designed for the virus that’s out there. And again, based on everything we have seen so far- all the data suggests it should be very effective against the new variants.” -Dr Jha, White House Covid-19 Response Coordinator

It’s quite bizarre that he refers to the two brands of mRNA shots in the singular as if they are indistinguishable and inseparate products.

Also, contrast his claim of the boosters being “essentially a reformulation of something that we’ve already used”

The government and corporate press are saying the shots may be hitting pharmacy shelves “by early to mid-September”

The United States have already purchased 66 million doses of these almost entirely untested shots from Moderna and another 105 million mostly untested shots from Pfizer.

It’s ambiguous what strains the Moderna vax the US will receive will target. I would guess BA1 & Original strains based on other Moderna purchase orders other countries are announcing (see below). It seems like the above HHS press release is written so people think the Moderna update will be for BA4/BA5

Immunobridging All Of Humanity From A Study With 8 Rats

A brand new piece from ArsTechnica published August 22, 2022 claims to have received a response from a Pfizer spokesperson about the data they had for their BA4-BA5 shots.

“Pfizer noted that it only had efficacy data on its BA.4/5 bivalent booster from mice. In eight mice, the BA.4/5 bivalent booster generated about a 2.6-fold increase in neutralizing antibody levels against the BA.4/5 subvariants compared with the companies' current booster.” ArsTechnica

UK Government Admits “No Data On The Clinical Efficacy” For “Currently Circulating Strains” & Protection Duration Unknown

In the UK Joint Committee on Vaccination and Immunisation (JCVI) report on Aug 15th, 2022 makes some staggering claims when you consider how little testing is going into vaccine development:

And that’s for BA1 vax, it sounds like there’s EVEN LESS data behind the BA4/BA5 vax.

UK Gives Conditional Authorization To Mostly Untested Omicron Boosters

On August 15th, the UK “granted conditional authorization” to Moderna, according to the company’s press release. Canada appears to also be purchasing the Moderna BA1/ original strain bivalent combo.

Interestingly, Pfizer CEO Albert Bourla is quoted in a Aug 22, 2022 Pfizer press release saying the production had already been ramped up for the BA4-BA5 bivalent shots and they “will be available to ship immediately”:

“Having rapidly scaled up production, we are positioned to immediately begin distribution of the bivalent Omicron BA.4/BA.5 boosters, if authorized, to help protect individuals and families as we prepare for potential fall and winter surges.” Albert Bourla, Chairman & CEO Pfizer

Pfizer announced that their new shots are under a “rolling review” by the European Union. Rolling reviews allow regulators to start authorization process before all of the data is in. In a press release they add: “As clinical data become available, including data on immunogenicity against Omicron and its subvariants, it will be added to the rolling submission.”

They have also announced that they are applying for conditional marketing authorization with the EMA for their Omicron shots in the EU

“A conditional marketing authorization application has also been initiated with the European Medicines Agency (EMA) for the Omicron BA.4/BA.5-adapted bivalent vaccine and is expected to be completed in the coming days.” Pfizer press release Aug 22 2022

‘It’s Impossible’: FDA’s Dr Susan Wollersheim Doesn’t Have a Clue

Dr Susan Wollersheim from FDA’s Office of Vaccine Research in June 15, 2022 made some stunning admissions. Dr. Hank Bernstein asked her about the clinical significance of a lower GMT after the 3 vaccine doses against Omicron than the prior variants:

That’s a great question because we’re not sure. We don’t have a correlate of protection. Additionally this is a nonvalidated assay that’s been used just to have this information so that we can see their is neutralization of these various viruses. The clinical interpretation though, I think is limited at this point, according to my understanding of what this assay shows.

When Dr Paul Offit asks Dr. Wollersheim why, for the first time, the Pfizer vaccine and Moderna diverged in the dose requirements (Pfizer says 3 shots required for children under 5), she says:

Great question, of course. I don’t want to say impossible but it’s difficult really to make these comparisons between these two vaccines. Umm So I would, you know- I dont think we can move there with the data that we have

The Plan All Along

Doran Fink & Peter Marks at the FDA have been working for a long time to transition to the brave, new (& possibly fraudulent) world of “immunobridging.” Weeks before the first EUA was issued for the Pfizer-BioNTech vaccine, Doran Fink said this on a webinar in October 2020:

“We do acknowledge that situations will likely arise where it is on longer ethically permissible and therefore no longer feasible to continue placebo controlled follow up in an ongoing trial, or to initiate a placebo controlled trial. In those situations, if widespread availability of a licensed Covid19 vaccine precludes use of the placebo comparator, then the licensed vaccine could be used as a comparator to evaluate relative vaccine efficacy of other vaccines, testing the confidence interval lower bound against a non-inferiority margin” -Doran Fink Oct 22, 2020 (src)

Here is a slide from a presentation Doran Fink gave on October 22nd, 2020: to introduce the insane concept of bringing “immunobridging” into the massive failure of the design and testing of the covid19 shots.. BEFORE the shots even got EUA’ed for a claimed 94-95% efficacy:

“We also recognize that there are some populations for which it may not be feasible to directly demonstrate vaccine effectiveness using a clinical disease endpoint. For example, pediatric population where the attack rate of symptomatic Covid19 disease is much lower than in adults. And so for these populations, following direct demonstration in another population, for example adults- as being evaluated in an ongoing phase 3 trial- the effectiveness of the vaccine can be inferred in the second population by immunobridging.” Doran Fink Oct 22, 2020

Just a couple of months later Peter Marks was asked by Dr Bailey, the president of the AMA, in January of 2021 (he was admittedly still not vaxxed at the time) about the potential need to address vaccines failing against variants

We have been trying to think about [rolling new vaccines out when variants make vaccines ineffective] for a while… We started to put together our thoughts about what this might look like. And we basically now are in the process of working with our industrial and federal partners to essentially put together a playbook… if we need to switch over to another sequence. For mRNA it’s very convenient, you just change a computer program for the synthesizing portion of this and you can change the vaccine… We are working on finalizing what [the FDA’s requirements] will look like. I can tell you what it will not require. It will not require a new clinical trial for efficacy. It will probably require some small clinical trials to just make sure that the vaccines are immunogenic, that they produce an immune response against these new variants.

AMA’s president then says “which is what we do with the flu vaccines.” Marks meekly confirms “yeah”. It gets worse. From the same interview, Marks continued lowering the federal government’s standards. When asked by the AMA’s president “So you won’t have to go through a completely new clinical trial? Will the authorization process be the same? It sounds like it will be pretty condensed” Marks replies

We would assume to have a pretty streamlined process. It’s possible we’ll go to our advisory committee to make sure that they’re confident with the data the first time. And my guess is the first- if we have to do this, the first times we’ll do it we’ll probably try to figure out how to do it. It may be that with time we might need even less data.. But the first time we do it, we may require some- we’ll probably require some clinical study. But as I say, not as an efficacy endpoint but probably with an immune response endpoint. It will probably not be very, very large studies. We will probably have hundreds of people, not thousands of people… We would try to be pretty nimble with this… so that we get these variants covered as quickly as possible

On a press conference with MSM reporters in June 2022, after FDA amended Moderna’s and Pfizer’s EUAs to include children 6 months - 5 years, Peter Marks showed his disqualifying, markedly anti-scientific sellout tendencies:

As we move into the younger age ranges with boosters, we won’t have to do the same kind of waiting because we now have the immunobridging we need. We now understand what the doses are correct for these populations. And so much as the same way that we may change the strains in older individuals, we be able to change strains in younger individuals. And we won’t have- I do not anticipate- any substantial delays here if we decide that younger individuals need an updated strain

And since we’re discussing foreknowledge, let’s reexamine Fauci’s comments at the Milken institute’s 2019 meeting on “Universal Flu Vaccines” on C-SPAN 2. In response to Michael Specter of the New Yorker openly pondering to get people to take untested vaccines.

“So we really do have a problem with how the world perceives influenza and it’s going to be very difficult to change that unless you do it from within and say: “I don’t care what your perception is, we’re going to address the problem. In a disruptive way and in an iterative way. Because you do need both.

Marks’ FDA Abandons 50% Short Term Efficacy Requirement

Dr. Peter Marks of the FDA gave a briefing about the C19 vaccines for children on May 6, 2022. The Coronavirus Subcommittee released a press release to pass along the new that the FDA no longer seems to care about the efficacy criteria.

I remember the July 2020 Energy Subcommittee meeting well where we were assured by both the pharma companies and committee members that “no corners would be cut” and if the products weren’t sufficiently safe and effective they would be scrapped and never brought to market.

Final Thoughts

Let’s conclude by appreciating how ridiculous it is that we find ourselves facing the rollout of shots #5+, driven by people who still claim that the vaccines “worked” and are “effective.” For those of us who have been vigilantly following the relentless attack on our freedom, we’ve seen how the authorities have purposely buried, obscured and misconstrued crucial evidence from public scrutiny. Yet we’re still being bullied into suspending our disbelief and rolling up our sleeves for infinite shots, all while mindlessly repeating the mantras of “safe & effective” and “no shortcuts were taken.” I could never be so illogical. This is perhaps more ridiculous than the 1984 analog, the simple mathematical falsehood that 2+2=5

Instead of actually learning how the human body works and designing effective vaccines for human betterment, big pharma hides behind their protective loopholes and redefines success to include lucrative failure.

Much more coming in future posts about the departure from even the illusion of science - see you there!